<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5163">
  <stage>Registered</stage>
  <submitdate>25/03/2014</submitdate>
  <approvaldate>25/03/2014</approvaldate>
  <nctid>NCT02099123</nctid>
  <trial_identification>
    <studytitle>A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)</studytitle>
    <scientifictitle>A Study of STAtins for Reducing Events in the Elderly (STAREE)</scientifictitle>
    <utrn />
    <trialacronym>STAREE</trialacronym>
    <secondaryid>NHMRC 1068146</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Independent Living</healthcondition>
    <healthcondition>Disability Free Survival</healthcondition>
    <healthcondition>Elderly</healthcondition>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Atorvastatin
Treatment: drugs - Placebo (for Atorvastatin)

Experimental: Atorvastatin - 40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily

Placebo Comparator: Placebo - Placebo (2 x 20 mg placebo) taken orally once daily


Treatment: drugs: Atorvastatin
Atorvastatin 20 mg tablet

Treatment: drugs: Placebo (for Atorvastatin)
Inactive pill manufactured to mimic Atorvastatin 20 mg tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>(i) to death or development of dementia (as measured by cognitive function tests) or development of disability (as measured by the KATZ ADL test), or (ii) to a major fatal or non-fatal cardiovascular event. - The primary endpoint is either the time from randomisation (i) to death or development of dementia (as measured by cognitive function tests) or development of disability (as measured by the KATZ ADL33 test), or (ii) to a major fatal or non-fatal cardiovascular event.</outcome>
      <timepoint>Time from randomisation to a primary endpoint</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular death - Fatal cardiovascular events</outcome>
      <timepoint>From date of randomisation until the date of a death to a cardiovascular cause</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mycocardial infarction</outcome>
      <timepoint>From date of randomisation until the date of of diagnosis of a myocardial infarction</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalisations - Hospitalisation reasons and length of stay</outcome>
      <timepoint>From date of randomisation until the date of hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>New onset diabetes - New diagnosis of diabetes</outcome>
      <timepoint>From date of randomisation until the date of diagnosis of diabetes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fatal and Non-fatal Cancer - Fatal and Non-fatal Cancer (excluding non-melanoma skin cancer)</outcome>
      <timepoint>From date of randomisation until the date of death due to cancer or date of first date of first cancer event</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive decline - Cognitive decline as assessed using the 3MS excluding depression</outcome>
      <timepoint>From date of randomisation until the date of a change in the 3Ms resulting in a diagnosis of cognitive decline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life - Quality of life (measured by the Short Form Health Survey (SF-36) administered at every second year of follow-up).</outcome>
      <timepoint>Assessed annually</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost-effectiveness of statin - Cost-effectiveness of statin</outcome>
      <timepoint>Up to 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stroke - Stroke can be a) haemorrhagic or b) thromboembolic</outcome>
      <timepoint>From date of randomisation until the date of a diagnoses stroke</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Approved need for permanent residential care - ACAS report</outcome>
      <timepoint>Approved need for residential care as reported by the Aged care assessment team</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All cause dementia - All-cause dementia (COWAT, Stroop test, Trail Making Test, HVLT-R, SDMT, ADAS-Cog, Lurian overlapping figures)</outcome>
      <timepoint>All cause dementia as assessed by cognitive tests</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frailty/Disability - KATZ-ADL administered every 6 months</outcome>
      <timepoint>As assesed using the KATZ-ADL</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and women aged =70 years living independently in the community

          -  Willing and able to provide informed consent and accept the study requirements (Note:
             competent physical ability to participate in the trial is assessed using the KATZ ADL
             questionnaire)</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>A history of cardiovascular disease (defined as myocardial infarction, stroke, peripheral
        vascular disease, angina, transient ischaemic attack, coronary artery angioplasty and/or
        stenting, coronary artery bypass grafting or heart failure),

          -  A history of dementia or a 3MS score &lt;78 on screening,

          -  A history of diabetes,

          -  Total cholesterol &gt;7.5 mmol/L,

          -  Moderate or severe chronic kidney disease (persistent proteinuria (Urine
             albumin:creatinine ratio &gt;30mg/mmol or Urine protein:creatinine ratios &gt;45 mg/mmol)45
             and/or eGFR &lt;45ml/min/1.73m2),

          -  Moderate or severe liver disease (persistent elevations of transaminases of more than
             3 times the upper limit of the normal laboratory reference range),

          -  Serious inter-current illness likely to cause death within the next 5 years such as
             terminal cancer or obstructive airways disease,

          -  Current participation in a clinical trial (Note: If yes, this is only an exclusion if
             other trial involves taking a drug or another intervention)

          -  Absolute contraindication to statin therapy,

          -  Current use of statin therapy or other lipid lowering therapy for primary prevention
             and unwilling to stop therapy,

          -  Current long term or permanent use of the following cytochrome P450 (CYP) 3A4
             inhibitors : Amiodarone, Boceprevir, Cimetidine, Cyclosporin, Danazol, Fosamprenavir,
             Indinavir, Lopinavir + Ritonavir, Erythromycin, Fluconazole, Itraconazole,
             Ketoconazole.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>TAS,VIC</recruitmentstate>
    <hospital>Tasmania - Hobart</hospital>
    <hospital>Victoria - Melbourne</hospital>
    <hospital>Queensland - Brisbane</hospital>
    <hospital>New South Wales - Newcastle</hospital>
    <hospital>Western Australia - Perth</hospital>
    <postcode> - Hobart</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Newcastle</postcode>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The STAREE study will examine whether treatment with statin (atorvastatin 40mg) compared with
      placebo will prolong overall survival or disability free survival amongst healthy elderly
      people (=70 years).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02099123</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sophia Zoungas, MBBS, FRACP</name>
      <address>Monash University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>